Mounjaro Lawsuit

Mounjaro is a type 2 diabetes drug developed by Eli Lilly. The drug is taken once weekly through an injection. Patients start with a low dosage of 2.5 mg and increase at regular intervals under the supervision of their doctor. Mounjaro was approved by the U.S. Food and Drug Administration (FDA) in 2022.

The active ingredient in Mounjaro is tirzepatide. It simulates two separate types of hormones. This makes the drug both:

• A glucose-dependent insulinotropic polypeptide (GIP) receptor
• A glucagon-like peptide-1 receptor agonist (GLP-1 RA)

These two hormones help regulate blood sugar levels. They help the brain understand when to increase or decrease insulin production.

Mounjaro can make people feel full and decrease appetite, which sometimes results in weight loss. In this way, Mounjaro’s active ingredient, tirzepatide, is similar to semaglutide, the active ingredient in Ozempic®, Rybelsus® and Wegovy®. 

Doctors and researchers are still unsure why semaglutide and tirzepatide are effective weight loss drugs, so research is ongoing.

Mounjaro, like Ozempic, isn’t approved by the FDA for weight loss. Using Mounjaro for weight loss is an off-label use and may come with safety risks.

Eli Lilly releases a tirzepatide drug for weight loss

In November 2023, the FDA approved Zepbound, another tirzepatide drug manufactured and sold by Eli Lilly. Eli Lilly created Zepbound to handle the growing off-label weight-loss use of Mounjaro. 

Zepbound is nearly identical to Mounjaro, but with a different prescribed dosage of tirzepatide. However, it is specifically approved for weight loss, not diabetes management. 

While all medicines come with warnings about potential side effects, many people are concerned about health issues that aren’t on Mounjaro’s warning label. 

Many of these side effects are gastrointestinal problems:

• Gastroparesis: This condition is sometimes referred to as “paralyzed stomach,” “stomach paralysis,” or “delayed gastric emptying.” It may cause a person’s stomach to slow or stop moving food through the digestive system. The delayed gastric emptying keeps food in the stomach, leading to potential complications. These complications include abdominal pain, acid reflux, nausea, vomiting and more. It may result in weight loss, malnutrition and severe dehydration.

• Gastroenteritis: This condition is an inflammation of both the stomach and intestines. It may lead to diarrhea, nausea and vomiting. If left untreated, gastroenteritis can leave a person severely dehydrated, which could come with additional complications.

Mounjaro’s label does warn users that it can cause severe gastrointestinal issues and isn’t recommended for people who have preexisting gastroparesis. But gastroparesis is not listed as a side effect on the warning label. These gastrointestinal conditions, which can severely impact a person’s life, are the basis of some personal injury lawsuits.

Other gastrointestinal issues have also been linked to GLP-1 drugs like Mounjaro. Chronic cyclical vomiting and intestinal obstructions are other serious Mounjaro side effects.

People are filing Mounjaro lawsuits against Eli Lilly. These lawsuits allege serious harm from using the type 2 diabetes drug. The plaintiffs say that they’ve suffered conditions such as gastroparesis and that Eli Lilly failed to warn users about these serious risks.

Mounjaro lawsuits include claims of:

• Failure to warn consumers: Some plaintiffs allege that Eli Lilly was required to disclose to patients all of the drug’s potential harms. They claim that Eli Lilly either knew or should have known they could be injured by Mounjaro. A failure-to-warn lawsuit can help push for proper labeling on drugs, which helps future patients understand all associated risks.
• Breach of express warranty: Plaintiffs also allege Eli Lilly portrayed Mounjaro on its label and through advertisements as safe and not prone to cause serious conditions, such as gastroparesis. If this express warranty hadn’t been present, plaintiffs may not have used Mounjaro and experienced health complications.

Plaintiffs in a Mounjaro lawsuit may seek damages for:

• Healthcare costs from the treatment of Mounjaro complications
• Pain and suffering experienced as a result of health issues
• Attorney’s fees for the costs of pursuing justice against Eli Lilly
• Punitive damages to punish Eli Lilly for its alleged disregard for public safety

The specific actions and damages of any Mounjaro lawsuit will depend on the facts of the case. Speaking with a Mounjaro lawyer can help you understand if you’re eligible to file a lawsuit against Eli Lilly.

What is the Mounjaro MDL?

Lawsuits against Eli Lilly for Mounjaro are currently being litigated in the U.S. District Court for the Eastern District of Pennsylvania as part of a larger multidistrict litigation (MDL). This MDL is known as In re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094.

Plaintiffs who allege harm from taking GLP-1 RA drugs such as Ozempic, Rybelsus, Wegovy, Mounjaro and Trulicity have filed lawsuits as part of the MDL. 

The purpose of an MDL is to help federal courts efficiently handle claims against similar defendants. Grouping clients together makes MDLs similar to class action lawsuits despite important differences:

• Each plaintiff’s case is tried separately in an MDL.
• Verdicts and settlements in an MDL are specific to each plaintiff, not equally divided as with a class action lawsuit. 

If you’ve taken Mounjaro as directed by a doctor and experienced one or more digestive side effects, you may be eligible to file a Mounjaro lawsuit. Individuals who developed gastroparesis while using Mounjaro should consider speaking with an attorney to explore possible legal action against Eli Lilly.

People who may be eligible for a case include those who:

• Had a prescription for Mounjaro
• Followed the instructions as directed
• Developed a side effect not listed on the package, such as gastroparesis

Determining eligibility for a Mounjaro lawsuit may be complicated. Speaking with an attorney who has experience handling medical drug claims can help you understand if you have a valid claim. An attorney can tell you what steps you need to take to file a Mounjaro suit.

If you’re eligible, a Mounjaro lawyer at Motley Rice can help you by:

• Gathering evidence: A lawyer may be able to help you understand what documentation is needed for your claim. Depending on the circumstances, they may be able to request documents from medical providers for you.
• Investigating your harm: It may be difficult to fully assess what you’ve suffered. A lawyer can help you investigate medical costs, lost wages and other damages you may be eligible to recover.
• Building your case: Filing a Mounjaro lawsuit is complex. A Mounjaro lawyer can help you by identifying what is necessary to build a claim.
• Litigating your claim: A Mounjaro lawyer can litigate the claim on your behalf in court.

The medical drug lawyers at Motley Rice have experience helping people navigate lawsuits for diabetes medications. Consider reaching out for a free consultation today.

Is there a Mounjaro class action lawsuit?

No, a Mounjaro class action lawsuit has not been filed as of February 2025, but a Mounjaro GLP-1 MDL has been created.

MDLs are similar to class action lawsuits in that multiple plaintiffs’ claims against specific defendants are consolidated before one court. However, unlike class actions, each plaintiff’s case in an MDL remains individually active. MDL cases can go to trial and any verdicts or settlements can be specific to the harm that each plaintiff has suffered. Class action awards are split between all plaintiffs.

What is the difference between Ozempic and Mounjaro?

The difference between Ozempic and Mounjaro is their active ingredient. Ozempic is a formulation of semaglutide, a GLP-1 receptor agonist, and is FDA-approved to reduce cardiovascular risks. Mounjaro is a formulation of tirzepatide, a GIP receptor and GLP-1 receptor agonist. They are both approved to help people with type 2 diabetes.

Ozempic and Mounjaro are both the subjects of ongoing litigation for injuries.

Read more about the risks of Ozempic.

What is the difference between Wegovy and Mounjaro?

The difference between Wegovy and Mounjaro is in their active ingredients. Wegovy, like Ozempic, uses the GLP-1 receptor agonist semaglutide. Mounjaro uses tirzepatide, which is both a GLP-1 receptor agonist and GIP receptor. Wegovy, unlike Mounjaro and Ozempic, has been approved for weight loss by the FDA.

Novo Nordisk, manufacturer of Wegovy and Ozempic, and Eli Lilly, manufacturer of Mounjaro, are defendants in personal injury lawsuits.

Read more about the risks of Wegovy.

Our medical attorneys have represented thousands of patients seriously hurt by dangerous prescription and over-the-counter drugs. We understand that as a patient or family member, what you know about your or a loved one’s medications may be limited.

If you believe a medicine made you sick or hurt you, our attorneys have the resources needed to thoroughly investigate and:

• Identify potentially harmful medicines
• Review if the medicine hurt you
• Review the medicine manufacturer’s compliance with FDA regulations
• Examine the adequacy of the manufacturer’s warning about potential side effects
• Recognize other issues that could affect your potential claim

Learn more about our law firm’s medical drug lawsuit experience here.

Do not stop taking a prescribed medication without first consulting with your doctor. Discontinuing a prescribed medication without your doctor’s advice can result in injury or death. Ozempic, Wegovy, Mounjaro and Rybelsus remain approved by the U.S. Food and Drug Administration.